This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adoption Of IsoRay's Cesium-131 Treatment For Lung Cancer Gains Momentum Using Da Vinci Robotics System

Stocks in this article: ISR

IsoRay, Inc. (Amex: ISR) said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) for use in conjunction with the da Vinci® Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

In recently published comments, Archbold Memorial Hospital announced it has become the first in the state of Georgia, "to revolutionize surgical treatment for lung cancer using mesh brachytherapy and the da Vinci Robot." General and thoracic surgeon Edward Hall, MD, and radiation oncologist Steven Johnson, MD, of Archbold’s Lewis Hall Singletary Oncology Center performed the surgery on a 64-year old female patient. To hear more about the doctors' experience and what the patient has to say, follow this link.

According to radiation oncologist Johnson, “ With mesh brachytherapy, patients benefit from getting the most targeted radiation possible, which decreases the chance of the cancer recurring and decreases the amount of potential lung damage...placing Cesium (131), a radioactive chemical element used for treating cancer, over the suture line reduces the risk of cancer recurrence in patients to 10 percent or less,” said Johnson.

IsoRay's Cesium-131 mesh brachytherapy gives physicians and their patients a viable treatment option for those cancer patients who otherwise would be inoperable because of limited pulmonary function or other health issues. Patients accrue additional benefits because targeted radiation does not involve the many weeks of treatment required in traditional external radiation since it can be done at the time of surgery and does not involve return trips to the hospital, except for routine follow-up visits. Cesium-131 brachytherapy treatments are demonstrating their efficacy in cancer control and survivability as well as in their positive impact on quality of life for patients.

IsoRay CEO Dwight Babcock says the combination of da Vinci robotics and his company's Cesium-131 mesh brachytherapy is proving a winning combination,"We are hearing from a number of physicians and medical facilities, who are looking at applications to treat a variety of cancers throughout the body. We are confident that this interest and excitement will translate into important benefits for patients who are fighting the toughest battles of their lives. This is about cancer control and survival and it comes with improved quality of life. I continue to believe that it's the insurance policy no patient can afford to be without. "

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years. In addition to its CMS codes, Cesium-131 is FDA-cleared for the treatment of prostate , lung , ocular melanoma , brain, colorectal, gynecological, and head and neck cancer and other cancers throughout the body.

About IsoRay, Inc.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,341.36 +272.49 1.60%
S&P 500 2,000.83 +28.09 1.42%
NASDAQ 4,617.6680 +69.8340 1.54%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs